Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Dynein light chain Tctex-type 1 (TCTEX-1), encoded by the DYNLT1 gene, is a critical component of the cytoplasmic dynein-1 motor complex (UniProt: P63172). It serves as a light chain subunit that functions primarily as a cargo-binding adapter, linking specific cellular components to the dynein motor for retrograde transport along microtubules (NCBI Gene: 6993). Beyond its structural role in the motor complex, TCTEX-1 participates in various signaling pathways, including the regulation of G-protein signaling and the modulation of actin cytoskeleton dynamics (PubMed: 11500494). It is essential for processes such as neurite outgrowth, ciliogenesis, and the maintenance of Golgi apparatus integrity (PubMed: 21670209). In the context of disease, TCTEX-1 is frequently exploited by various viruses, such as Rabies and HIV-1, which bind to the protein to facilitate their transport toward the host cell nucleus (PubMed: 15548690). Additionally, TCTEX-1 is often overexpressed in several types of cancer, where it contributes to increased cell proliferation, migration, and invasion (PubMed: 25663484). While no FDA-approved drugs currently target TCTEX-1, it is an active area of research for developing small-molecule inhibitors and competitive peptides to block viral entry and tumor progression. Therapeutic strategies focus on disrupting the protein-protein interactions between TCTEX-1 and its diverse array of cargo or signaling partners.
Inhibition of dynein-mediated retrograde transport and disruption of specific protein-protein interactions between the light chain and its cargo (PubMed: 15548690).
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dynein light chain Tctex-type 1 (DYNLT1) (TCTEX-1).